All News
Why treatment of pre-RA isn't ready for prime time
The ACR Great Debate was on "To treat or not to treat in pre-RA?". What is the clinician to do?
Read Article
Imaging in PMR
Despite the fact that polymyalgia rheumatica is the most prevalent inflammatory rheumatic disease in those over 65 years of age, progress in its diagnosis, monitoring and management have failed to garner momentum in decades past.
However, ACR22 has fostered significant promise for its future.
ACR 2022 Appraisal, Praise & Critique (11.18.2022)
It was great to be back at an ACR annual meeting, this one in Philadelphia - Philly was great. A walking town, rich in culture, history and good places to meet and mingle.
I loved the city, but not the convention center (not easy to navigate).
Read Article
Opioids and Health Care Utilization in PsA and AS
Dr Aurelie Najm ( @AurelieRheumo) discusses Abstract 0402 presented at #ACR22. Abstract 0402: Opioid Use and Healthcare Utilization in Adults with PsA and AS
https://t.co/trruZGyIVf https://t.co/8kj9vpKPlD
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Ted Mikuls has authored a Clinical practive review of Gout in this weeks New England Journal of Medicine - Congrats Ted! https://t.co/8MuC6upkOT https://t.co/zO4nZbWQ5A
Links:
Dr. John Cush RheumNow ( View Tweet)
Retrospective review of 185 hospitalized AOSD pts (incidence 0.16 - 0.21/100K); Mean age 47 (70% female), mean ESR 55, CRP 12.26, ferritin 7141 WBC 12.15, anemia 23%. 24% ICU care & overall mortality was 3.2%. Ab#0829 #ACR22 https://t.co/eDRY4b3GAg https://t.co/3pt0ZH5QQH
Links:
Dr. John Cush RheumNow ( View Tweet)
Best of PsA on Day 1
Dr. Rachel Tate ( @uptoTate) discusses the best PSA data presented 11/12 at #ACR22
https://t.co/i93CX7wic3 https://t.co/dQDOcIsu1P
Links:
Dr. John Cush RheumNow ( View Tweet)
#ACR22 - Day 2 Part III
RheumNow and its reporters review abstracts presented on Day 2 of #ACR22.
https://t.co/uUiX7s5Ajf https://t.co/0E5KSpOyyL
Links:
Dr. John Cush RheumNow ( View Tweet)
Survival and Mortality in RA: time to move away from “one-size fits all”?
Dr. Aurelie Najm ( @AurelieRheumo ) reviews Abstract #0246 at #ACR22.
https://t.co/O4dNzCZmmd https://t.co/cWUXEpduID
Links:
Dr. John Cush RheumNow ( View Tweet)
Exciting Data for SLE: Plenaries from #ACR22
Dr. Michael Putman ( @EBRheum ) shares SLE updates shared at #ACR22.
https://t.co/34HAvc2S8F https://t.co/xINo52fF2O
Links:
Dr. John Cush RheumNow ( View Tweet)
Can computers tell the difference between RA & PsA?
Dr. David Liew ( @drdavidliew) discusses Abstract 0242 presented at #ACR22. Abstract 0242: Neural Networks for Distinguishing RA from PsA by Using Magnetic Resonance Imaging
https://t.co/ZL5TYIdT6Q https://t.co/tZWIAl0rb0
Links:
Dr. John Cush RheumNow ( View Tweet)
Upadacitinib vs Adalimumab in PsA using RAPID3
Dr. Catherine Sims ( @DrCassySims) discusses abstract 0192 presented at #ACR22. 0192: Upadacitinib versus Adalimumab on Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with PsA,
https://t.co/nRjgM45GdO https://t.co/MDqpW7ACXa
Links:
Dr. John Cush RheumNow ( View Tweet)
#ACR22 Rheumatology Roundup w/ Drs. Kavanaugh & Cush
#1044 Combo Rx SpA
#0533 CCP spit
#1604 StopRA
#2251 Tofa & RA ILD
#0420 NSAID SpA
#002 CA in IIM
#0113 BTK Sjogrens
#L05 Prolia EOA
#0526 Pexivas
#1106 TCZ PMR
Video: https://t.co/JG3spEsYDD
Podcast: https://t.co/nbmeiGo2yt https://t.co/E7RDPTFsaS
Dr. John Cush RheumNow ( View Tweet)
Urinary Biomarkers in Lupus
Dr.Cush interviews Dr. Fava about Abstract 536 at #ACR22. Abstract 0536: Change in Urinary Biomarkers at Three Months Predicts 1-year Treatment Response of Lupus Nephritis Better Than Proteinuria
https://t.co/3IfPdTMufb https://t.co/XVECG9mJri
Links:
Dr. John Cush RheumNow ( View Tweet)
Social Media in Academic Rheumatology
Dr. Kathryn Dao and Jorena Lim discuss the impact of social media in rheumatology. @KDAO2011
https://t.co/a6yoH745Ap https://t.co/RioB7n9fWZ
Links:
Dr. John Cush RheumNow ( View Tweet)
Dual target blockade may be better than one in SLE
Dr. Yusof ( @Yuz6Yusof) discusses abstracts #L07 and #1001 presented at #ACR22.
https://t.co/20MGDHBLT1 https://t.co/4IcBKn1IKg
Links:
Dr. John Cush RheumNow ( View Tweet)
Repetitive Testing of Anti-dsDNA Antibodies May Predict Flares in SLE
Dr. Sheila Reyes ( @RHEUMarampa ) summarizes abstract #0327 presented during the poster session at #ACR22.
https://t.co/kSFfyRIQXZ https://t.co/bVTE9VsFmC
Links:
Dr. John Cush RheumNow ( View Tweet)
Poor Medication Adherence in SLE and How to Improve It
Dr. Janet Pope ( @Janetbirdope) discusses three abstracts presented at #ACR22.
https://t.co/AWxj4fsTkt https://t.co/Lol1zG7C0q
Links:
Dr. John Cush RheumNow ( View Tweet)
2022 ACR/EULAR Classification Criteria for GCA
Dr. Michael Putman discusses interesting take-home messages from the Vasculitis Investigators Meeting at ACR22 Convergence regarding the 2022 ACR/EULAR Classification Criteria for GCA.
https://t.co/w7NE2Wpm95 https://t.co/vB94wS7ONF
Links:
Dr. John Cush RheumNow ( View Tweet)
To Beta Block or Not in GCA & Large Vessel Vasculitis
Dr. Harkins ( @DrTrishHarkins) discusses abstract 0477 presented at #ACR22.
Abstract 0477: Can Beta-blockers Prevent Aortic Dilation in Patients w/ Giant Cell Arteritis & Large Vessel Vasculitis?
https://t.co/cwA1Z5XrQr https://t.co/QGSS6RUBn3
Links:
Dr. John Cush RheumNow ( View Tweet)